| CKD | Chronic kidney disease |
| RRTs | Renal replacement therapies |
| DM | Diabetes mellitus |
| HT | Hypertension |
| ROS | Reactive oxygen species |
| DN | Diabetic nephropathy |
| CVD | Cardiovascular disease |
| ESRD | End-stage renal disease |
| GFR | Glomerular filtration rate |
| HD | Hemodialysis |
| PD | Peritoneal dialysis |
| NF-κB | Nuclear transcription factor kappa B |
| TNF-α | Tumor necrosis factor-alpha |
| IL-6 | Interleukin-6 |
| IL-1β | Interleukin-1 beta |
| IS | Indoxyl sulfate |
| ADMA | Asymmetric dimethylarginine |
| NO | Nitric oxide |
| DKD | Diabetic kidney disease |
| SIRT1 | Sirtuina 1 |
| HMGB1 | High Mobility Group Box 1 |
| NLRP3 | NOD-like receptor family pyrin domain containing 3 |
| CKD-5D | Chronic kidney disease stage 5 on dialysis |
| NADPH | Nicotinamide adenine dinucleotide phosphate |
| Nrf2 | Nuclear factor erythroid 2 |
| COX-2 | Cyclooxygenase-2 |
| C3G | Cyanidin-3-O-glucoside |
| ACR | Albumin/creatinine ratio |
| GSH | Glutathione |
| Del-3-sa-5-glu | Delphinidin-3-sambubioside-5-glucoside |
| Del-3,5-diglu | Delphinidin-3, 5-diglucoside |
| Ci-3-sa-5-glu | Cyanidine-3-sambubioside-5-glucoside |
| Ci-3,5-diglu | Cyanidin-3,5-diglucoside |
| Del-3-sa | Delphinidin-3-sambubioside |
| Del- 3-glu | Delphinidin-3-glucoside |
| Ci-3-sa | Cyanidin-3-sambubioside |
| Ci-3-glu | Cyanidin-3-glucoside |
| ORAC | Oxygen Radical Absorption Capacity |
| TPs | Total phenols |
| TFs | Total flavonoids |
| Ox-LDLs | Oxidized low-density lipoproteins |
| NOS | Newcastle-Ottawa scale |
| RoB | Risk of Bias Tool |
| RCTs | Randomized controlled trials |